{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:28:57Z","timestamp":1790641737986,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015804","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000}}],"reference-count":113,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015804.pub2","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T13:28:23Z","timestamp":1717421303000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration"],"prefix":"10.1002","volume":"2024","author":[{"given":"Tomiko","family":"Sunaga","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy; Showa University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Infection Control Sciences, Department of Clinical Pharmacy, School of Pharmacy; Showa University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Saulle","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Lazio Regional Health Service; Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sueko M","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado - Anschutz Medical Campus; Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki Takenaka","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy; School of Pharmacy, Showa University ; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology (iCE); Showa University; Tokyo Japan"},{"name":"Department of Hygiene, Public Health, and Preventive Medicine; Showa University School of Medicine; Tokyo Japan"},{"name":"Division of Nephrology, Department of Medicine; Showa University School of Medicine; Tokyo Japan"},{"name":"Showa University Research Administration Center (SURAC); Showa University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of General Education, School of Medicine; Juntendo University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Data Science; The Institute of Statistical Mathematics; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ota","sequence":"additional","affiliation":[{"name":"Global Health Nursing; St. Luke\u2019s International University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD015804.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Global Health"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Wilkinson","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"c981","DOI":"10.1136\/bmj.c981","article-title":"Age related macular degeneration","volume":"340","author":"Chakravarthy","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD015804.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"100852","DOI":"10.1016\/j.eclinm.2021.100852","article-title":"Global economic productivity losses from vision impairment and blindness","volume":"35","author":"Marques","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0007|cit7","unstructured":"Drug Approval Package: SYFOVRE www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217171Orig1s000TOC.cfm"},{"issue":"6","key":"10.1002\/14651858.CD015804.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archophthalmol.2011.140","article-title":"Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration","volume":"129","author":"Bressler","year":"2011","journal-title":"Archives of Ophthalmology"},{"issue":"10153","key":"10.1002\/14651858.CD015804.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD015804.pub2-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD015804.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015804.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1755-3768.2012.02493.x","article-title":"Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study\u2014a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany","volume":"91","author":"Finger","year":"2013","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2147\/OPTH.S68293","article-title":"Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life","volume":"8","author":"Inoue","year":"2014","journal-title":"Clinical Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD015804.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00417-016-3477-9","article-title":"Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration","volume":"255","author":"Zhu","year":"2017","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD015804.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","article-title":"Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States","volume":"138","author":"Mulligan","year":"2020","journal-title":"JAMA Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD015804.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archophthalmol.2010.19","article-title":"Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis","volume":"128","author":"Campbell","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD015804.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ophtha.2007.04.016","article-title":"Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999","volume":"115","author":"Coleman","year":"2008","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD015804.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ajo.2011.05.008","article-title":"Medicare costs for neovascular age-related macular degeneration, 1994-2007","volume":"152","author":"Day","year":"2011","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD015804.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.ophtha.2016.01.042","article-title":"Treatment patterns and health care costs for age-related macular degeneration in Japan: an analysis of national insurance claims data","volume":"123","author":"Kume","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD015804.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/IAE.0b013e31826f065e","article-title":"Costs of newly diagnosed neovascular age-related macular degeneration among Medicare beneficiaries, 2004-2008","volume":"33","author":"Qualls","year":"2013","journal-title":"Retina"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajo.2018.04.008","article-title":"Estimating medicare and patient savings from the use of bevacizumab for the treatment of exudative age-related macular degeneration","volume":"191","author":"Rosenfeld","year":"2018","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0023|cit23","unstructured":"National Institute for Health and Care Excellence Age-related macular degeneration www.nice.org.uk\/guidance\/ng82\/resources\/agerelated-macular-degeneration-pdf-1837691334853"},{"issue":"11","key":"10.1002\/14651858.CD015804.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/eye.2016.154","article-title":"Licence to save: a UK survey of anti-VEGF use for the eye in 2015","volume":"30","author":"Shalaby","year":"2016","journal-title":"Eye"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.eclinm.2022.101354","article-title":"The economics of vision impairment and its leading causes: a systematic review","volume":"46","author":"Marques","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1002\/14651858.CD015804.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.18553\/jmcp.2021.27.9.1260","article-title":"Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis","volume":"27","author":"Almony","year":"2021","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"27","key":"10.1002\/14651858.CD015804.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.2147\/DDDT.S368963","article-title":"Spotlight on faricimab in the treatment of wet age-related macular degeneration: design, development and place in therapy","volume":"16","author":"Nair","year":"2022","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"American Journal of Ophthalmology Case Reports"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/jcm10050981","article-title":"Inflammatory complications of intravitreal anti-VEGF injections","volume":"10","author":"Cox","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","article-title":"Brolucizumab and immunogenicity","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (London, England)"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"Journal of VitreoRetinal Diseases"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0035|cit35","unstructured":"European Medicines Agency Guideline on similar biological medicinal products www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-first-version_en.pdf"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0036|cit36","unstructured":"Questions and answers on biosimilar development and the BPCI Act guidance for industry www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/questions-and-answers-biosimilar-development-and-bpci-act-guidance-industry"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0037|cit37","unstructured":"Ministry of Health Guidelines for the quality, safety and efficacy assurance of follow-on biologics www.pmda.go.jp\/files\/000153851.pdf"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0038|cit38","unstructured":"Review and approval www.fda.gov\/drugs\/biosimilars\/review-and-approval"},{"issue":"2","key":"10.1002\/14651858.CD015804.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4103\/ijo.IJO_2703_20","article-title":"Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey","volume":"69","author":"Sheth","year":"2021","journal-title":"Indian Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0040|cit40","unstructured":"European Medicines Agency Byooviz www.ema.europa.eu\/en\/medicines\/human\/EPAR\/byooviz"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0041|cit41","unstructured":"Biosimilar Product Information www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0042|cit42","unstructured":"Yesafili www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yesafili"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0043|cit43","unstructured":"FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0044|cit44","first-page":"161","article-title":"Biosimilars: science, implications, and potential outlooks in the Middle East and Africa","volume":"16","author":"Batran","year":"2022","journal-title":"Biologics"},{"issue":"2","key":"10.1002\/14651858.CD015804.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","article-title":"Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price","volume":"34","author":"Dutta","year":"2020","journal-title":"BioDrugs"},{"issue":"7","key":"10.1002\/14651858.CD015804.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.37765\/ajmc.2022.88809","article-title":"Projected US savings from biosimilars, 2021-2025","volume":"28","author":"Mulcahy","year":"2022","journal-title":"American Journal of Managed Care"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/biom12111629","article-title":"Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.3390\/cells11213453","article-title":"A linkage between angiogenesis and inflammation in neovascular age-related macular degeneration","volume":"11","author":"Heloter\u00e4","year":"2022","journal-title":"Cells"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"Journal of Translational Medicine"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0050|cit50","unstructured":"US Department of Health and Human Services Medicare payments for drugs used to treat wet age related macular degeneration oig.hhs.gov\/oei\/reports\/oei-03-10-00360.pdf"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (London, England)"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging therapies in neovascular age-related macular degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia-Pacific Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","article-title":"Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases","volume":"30","author":"Nicol\u00f2","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"1","key":"10.1002\/14651858.CD015804.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488602","article-title":"Real-life clinical effectiveness of Razumab\u00ae (the world's first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT Study","volume":"241","author":"Sharma","year":"2019","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1002\/14651858.CD015804.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"68-76","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/jpgm.JPGM_109_19","article-title":"Pharmacovigilance of biosimilars\u2014why is it different from generics and innovator biologics?","volume":"65","author":"Oza","year":"2019","journal-title":"Journal of Postgraduate Medicine"},{"issue":"16","key":"10.1002\/14651858.CD015804.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.3390\/ijerph17165800","article-title":"Clinical and regulatory concerns of biosimilars: a review of literature","volume":"17","author":"Halimi","year":"2020","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"876503","DOI":"10.3389\/fphar.2022.876503","article-title":"Knowledge, attitudes and practice of healthcare providers, healthcare regulatory practitioners and patients toward biosimilars in China: insights from a nationwide survey","volume":"13","author":"Hu","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD015804.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e034183","DOI":"10.1136\/bmjopen-2019-034183","article-title":"Physicians' perceptions of the uptake of biosimilars: a systematic review","volume":"10","author":"Sarnola","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"10.1002\/14651858.CD015804.pub2-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015804","article-title":"Anti-vascular endothelial growth factor biosimilars for macular degeneration","author":"Sunaga","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmology Retina"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0062|cit62","unstructured":"National Institutes of Health Tool summary sheet: safety definitions for clinical research www.hhs.gov\/guidance\/sites\/default\/files\/hhs-guidance-documents\/2008112345-yi-safety-definition-clinicalrsrch.pdf"},{"issue":"7","key":"10.1002\/14651858.CD015804.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute visual function questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0064|cit64","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0065|cit65","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0066|cit66","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0067|cit67","unstructured":"Page MJ Higgins JP Sterne JAC Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0068|cit68","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0069|cit69","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0070|cit70","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"3087-95","DOI":"10.2147\/OPTH.S307746","article-title":"Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (wet) age-related macular degeneration","volume":"15","author":"Apsangikar","year":"2021","journal-title":"Clinical Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0072|cit72","unstructured":"Efficacy and safety of R-TPR-024 \/ Lucentis\u00ae in patients with neovascular (wet) age-related macular degeneration ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=23205&EncHid=&userName=CTRI\/2018\/05\/014065"},{"issue":"2","key":"10.1002\/14651858.CD015804.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","article-title":"Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product Lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3 randomized clinical trial","volume":"141","author":"Bressler","year":"2023","journal-title":"JAMA Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD015804.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"384-91","DOI":"10.1136\/bjophthalmol-2021-319637","article-title":"Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes","volume":"107","author":"Bressler","year":"2023","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0075|cit75","unstructured":"SB11 versus Lucentis\u00ae in subjects with neovascular age-related macular degeneration clinicaltrialsregister.eu\/ctr-search\/search?query=2017-000422-36"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0076|cit76","unstructured":"A study to compare SB11 (proposed ranibizumab biosimilar) to Lucentis in subjects with neovascular age-related macular degeneration (AMD) clinicalTrials.gov\/show\/NCT03150589"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0077|cit77","unstructured":"A study to compare SB11 (proposed ranibizumab biosimilar) to Lucentis in subjects with neovascular age-related macular degeneration (AMD) clinicaltrials.gov\/ct2\/show\/NCT03150589"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0078|cit78","unstructured":"A clinical trial study to compare the effects of two drugs SB11 (study drug) and Lucentis\u00c2\u00ae in subjects who have age related loss of vision ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=25196&EncHid=&userName=CTRI\/2018\/05\/013650"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0079|cit79","unstructured":"A study to comparing SCD411 and Eylea\u00ae in subjects with wet age-related macular degeneration (AMD) clinicalTrials.gov\/show\/NCT04480463"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0080|cit80","unstructured":"A phase III study of SCD411 in subjects with neovascular age-related macular degeneration jrct.niph.go.jp\/latest-detail\/jRCT2041210008"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0081|cit81","unstructured":"A clinical study to determine if a potential new drug (SCD411) is similar to the marketed product Eylea\u00ae in the efficacy, is safe and similar tolerable and distributed, by testing its effect on the body in patients with neovascular age-related macular degeneration clinicaltrialsregister.eu\/ctr-search\/search?query=2019-004132-37"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0082|cit82","unstructured":"This study is being done to compare the effectiveness and safety of study drug SCD411 (Aflibercept) and marketed product Eylea in treating wet age-related macular degeneration disease which occurs in eye ctri.nic.in\/Clinicaltrials\/pmaindet2.phprialid=45552&EncHid=&userName=CTRI\/2020\/08\/027015"},{"issue":"1","key":"10.1002\/14651858.CD015804.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"54-63","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0084|cit84","unstructured":"Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration clinicaltrials.gov\/study\/NCT02611778"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0085|cit85","unstructured":"Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-001961-20-HU"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0086|cit86","first-page":"11","article-title":"Randomized trial of biosimilar XSB-001 versus reference ranibizumab in patients with neovascular age-related macular degeneration","volume":"11","author":"Loewenstein","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0087|cit87","unstructured":"A study to determine the effectiveness and safety of the study drug Xlucane compared to Lucentis\u00ae in people with the wet form of age-related macular degeneration (wAMD) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-002930-19-SK"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0088|cit88","unstructured":"Comparing the efficacy and safety of biosimilar candidate Xlucane versus Lucentis\u00ae in patients with nAMD https:\/\/clinicaltrials.gov\/study\/NCT03805100"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0089|cit89","unstructured":"Comparing the efficacy and safety of Xlucane versus Lucentis\u00ae in patients requiring treatment of wet AMD ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=31240&EncHid=&modid=&compid=%27,%2731240det%27"},{"issue":"7","key":"10.1002\/14651858.CD015804.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial","volume":"141","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0091|cit91","unstructured":"A study to compare SB15 (proposed aflibercept biosimilar) to Eylea in subjects with neovascular age-related macular degeneration (AMD) clinicalTrials.gov\/show\/NCT04450329"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0092|cit92","unstructured":"A phase III clinical study to compare SB15 and Eylea\u00ae in patients with neovascular age-related macular degeneration clinicaltrialsregister.eu\/ctr-search\/search?query=2019-003883-28"},{"issue":"8","key":"10.1002\/14651858.CD015804.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"3008-14","DOI":"10.4103\/ijo.IJO_2118_21","article-title":"A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis\u00ae in patients with neovascular age-related macular degeneration","volume":"70","author":"Singh","year":"2022","journal-title":"Indian Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD015804.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1054-5","DOI":"10.4103\/IJO.IJO_2609_22","article-title":"Response to commentary on: a prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration","volume":"71","author":"Shah","year":"2023","journal-title":"Indian Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD015804.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"3014-5","DOI":"10.4103\/ijo.IJO_753_22","article-title":"Commentary: a prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with lucentis in patients with neovascular age-related macular degeneration","volume":"70","author":"Gopal","year":"2022","journal-title":"Indian Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0096|cit96","unstructured":"Clinical trial to compare effects and safety of Lupins ranibizumab with Lucentis\u00ae in patients with age-related loss of central vision trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2019\/03\/018322"},{"issue":"11","key":"10.1002\/14651858.CD015804.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"e0275611","DOI":"10.1371\/journal.pone.0275611","article-title":"Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: a phase 3 randomized clinical trial","volume":"17","author":"Yoon","year":"2022","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0098|cit98","unstructured":"A study to evaluate CKD-701 and Lucentis\u00ae in patients with neovascular (wet) age related macular degeneration clinicalTrials.gov\/show\/NCT04857177"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0099|cit99","unstructured":"A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degeneration center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000034245"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0100|cit100","unstructured":"Pharmaceuticals and Medical Devices Agency Ranibizumab (biosimilar) www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/1319407"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0101|cit101","unstructured":"Safety study of PF582 versus Lucentis in patients with age related macular degeneration who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12613001303730"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0102|cit102","unstructured":"Safety study of PF582 versus Lucentis in patients with age related macular degeneration clinicalTrials.gov\/show\/NCT02121353"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0103|cit103","unstructured":"Evaluating of the safety, pharmacokinetics and pharmacodynamics of QL1205 and Lucentis\u00ae in patients with wet AMD clinicalTrials.gov\/show\/NCT03312283"},{"issue":"8","key":"10.1002\/14651858.CD015804.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.oret.2017.12.006","article-title":"Medicare spending on anti-vascular endothelial growth factor medications","volume":"2","author":"Patel","year":"2018","journal-title":"Ophthalmoloy Retina"},{"issue":"9","key":"10.1002\/14651858.CD015804.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD015804.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"477\u201385","DOI":"10.1111\/ceo.13706","article-title":"Impact of out-of-pocket costs on patient initiation, adherence and persistence rates for patients treated with anti-vascular endothelial growth factor medicines","volume":"48","author":"Jackson","year":"2020","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD015804.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"508\u20139","DOI":"10.1111\/imj.14787","article-title":"Biologic therapy for uveitis: addressing access issues is paramount","volume":"50","author":"Robinson","year":"2020","journal-title":"Internal Medicine Journal"},{"issue":"3","key":"10.1002\/14651858.CD015804.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","article-title":"An introduction to biosimilars for the treatment of retinal diseases: a narrative review","volume":"11","author":"Hariprasad","year":"2022","journal-title":"Ophthalmology and Therapy"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1200\/OP.22.00502","article-title":"Medical oncologists' knowledge and perspectives on the use of biosimilars in the United States","volume":"19","author":"Peipert","year":"2023","journal-title":"JCO Oncology Practice"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14712598.2021.1982890","article-title":"Medical students' knowledge and awareness levels about biologics and biosimilars: the earlier the better?","volume":"22","author":"Dora","year":"2022","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"10.1002\/14651858.CD015804.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e001205","DOI":"10.1136\/bmjophth-2022-001205","article-title":"Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment","volume":"8","author":"Hatamnejad","year":"2023","journal-title":"BMJ Open Ophthalmology"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"101358","DOI":"10.1016\/j.ajoc.2022.101358","article-title":"Ranizurel safety evaluation in real-world -(RaSER) study","volume":"25","author":"Sharma","year":"2022","journal-title":"American Journal of Ophthalmology Case Reports"},{"key":"10.1002\/14651858.CD015804.pub2-BIB0113|cit113","unstructured":"Center for Drug Evaluation and Research (CDER) Scientific considerations in demonstrating biosimilarity to a reference product. U.S. Food and Drug Administration www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ scientific-considerations-demons"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T04:24:34Z","timestamp":1737951874000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015804.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":113,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015804.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}